Different nucleos(t)ide analogs in resected hepatitis B virus-associated hepatocellular carcinoma: a systematic review. [PDF]
BackgroundTo evaluate the effects of different types of nucleos(t)ide analogs on the survival rate of patients with hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) after radical resection through a network meta-analysis.MethodsPubMed ...
Qiu H, Zhang Y, Xu F, Xue S.
europepmc +7 more sources
Background/Aims: The aim of this study was to identify the predictors for relapse after discontinuation of oral nucleos(t)ide analog treatment for chronic hepatitis B (CHB).
Jie Peng +6 more
doaj +4 more sources
Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation [PDF]
The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence.
Mesut Akarsu +19 more
doaj +3 more sources
In the treatment of chronic hepatitis-B (CHB), although viral replication load is reduced with the use of nucleos(t)ide analogs, the risk of cirrhosis and hepatocellular carcinoma (HCC) remains. We aimed to investigate the relationship between metabolic syndrome (MetS) and CHB of nucleos(t)ide analogs, which are effective in mortality-morbidity.In ...
Yakut, Aysun, Aladağ, Murat
core +6 more sources
Distinct histological patterns in chronic hepatitis D with nucleos(t)ide analogue therapy [PDF]
BackgroundChronic hepatitis delta virus (HDV) infection leads to a more severe hepatitis than hepatitis B virus (HBV) infection alone. Specific histological staining patterns have been described in HBV mono-infection, however this has not been ...
Julian Hercun +4 more
doaj +2 more sources
Background: Antiviral therapy with nucleos(t)ide analogs for chronic hepatitis B is aimed at preventing disease progression and the development of complications.
T. H. Nguyen +4 more
doaj +2 more sources
Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008-2019. [PDF]
Background: Germany is a low prevalence country for hepatitis B virus (HBV) infection with higher prevalence in vulnerable groups. The number of treated chronic hepatitis B (CHB) patients is unknown.
Maisa A +8 more
europepmc +7 more sources
Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy [PDF]
Background The clinical manifestation of hepatocellular carcinoma (HCC) with hepatitis B virus (HBV) varies significantly between patients treated with or without nucleos(t) ide analog (NUC) therapy.
Li Liu
doaj +3 more sources
Etiologies of Persistent Aminotransferase Elevations in Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogs. [PDF]
Background/Aims: Recent studies revealed that patients with persistent aminotransferase elevations after antiviral treatment had higher risk of hepatic events; yet its underlying causes remain unclear.
Xiong QF +6 more
europepmc +4 more sources
Circulating miR-122 Is a Predictor for Virological Response in CHB Patients With High Viral Load Treated With Nucleos(t)ide Analogs. [PDF]
Chronic hepatitis B (CHB) infection remains worldwide health problem. Antiviral treatment options for CHB patients include nucleos(t)ide analogs (NAs) and interferon.
Wu Y +6 more
europepmc +4 more sources

